Survival Advantage With Adjuvant Chemotherapy for Locoregionally Advanced Rectal Cancer: A Veterans Health Administration Analysis

Daphna Y. Spiegel, Matthew J. Boyer, Julian C. Hong, Christina D. Williams, Michael J. Kelley, Joseph K. Salama, Manisha PaltaJournal of the National Comprehensive Cancer Network 2020 · DOI

Abstract

In this population of patients with LARC treated with neoadjuvant CRT and surgery, OS and DSS were improved among those treated with AC versus OBS. DSS benefits were seen with ≥4 months of AC. No additional benefit was observed with multiagent therapy. In the absence of phase III data, these findings support the use of AC for LARC.
BibTeX
@article{spiegel2020survival,
  author = {Daphna Y. Spiegel and Matthew J. Boyer and Julian C. Hong and Christina D. Williams and Michael J. Kelley and Joseph K. Salama and Manisha Palta},
  title = {{Survival Advantage With Adjuvant Chemotherapy for Locoregionally Advanced Rectal Cancer: A Veterans Health Administration Analysis}},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2020},
  doi = {10.6004/jnccn.2019.7329},
}

Loading related content...

Figure